Active, not recruiting

4

800

Europe, US

Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)

The Cleveland Clinic, University of Nottingham

Multiple Sclerosis, Relapsing-Remitting

07/27

09/30

Recruiting

4

8000

Europe, Canada, RoW

Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging

University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute

Staphylococcus Aureus Bacteremia

12/28

12/28